Ranolazine (Ranexa®) as an add-on therapy is recommended as an option for restricted use within NHS Wales for the symptomatic treatment of patients with stable angina pectoris. Treatment should be initiated by a Cardiologist. Ranolazine (Ranexa®) should be restricted for use in patients who remain symptomatic despite treatment with all other pharmacological anti-anginal therapies and where revascularisation has been considered and undertaken or is not considered appropriate.